SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

Inicio・Lista de Acciones・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Cerrado

Sector Salud

79.5 1.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

79.3

Máximo

79.65

Métricas clave
By Trading Economics
Ingresos	15M
Ventas	-297M 151M
P/B Media del Sector	24.61 106.547
BPA	0.292
Margen de beneficio	9.896
EBITDA	26M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+23.9 upside

Dividendos
By Dow Jones
Próximas Ganancias	7 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	137M 4.1B
Apertura anterior	77.64
Cierre anterior	79.5

Noticias sobre sentimiento de mercado

By Acuity

100%

371 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

76.2 / 80.2 Soporte y Resistencia

Laboratorios Farmaceuticos Rovi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 22:50 UTC

Acciones populares

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1 nov 2024, 22:43 UTC

Principales Movimientos del Mercado

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1 nov 2024, 22:13 UTC

Principales Movimientos del Mercado

Chewy Up 5% on S&P MidCap 400 Inclusion

1 nov 2024, 21:39 UTC

Ganancias

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2 nov 2024, 13:53 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov 2024, 13:44 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 13:00 UTC

Ganancias

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov 2024, 12:58 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:48 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov 2024, 12:32 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:28 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:17 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Net $26.25B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2 nov 2024, 09:30 UTC

Principales Noticias

Awful Jobs Report Aside, the Economy Is Still Strong -- Heard on the Street -- WSJ

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

1 nov 2024, 22:51 UTC

Ganancias

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1 nov 2024, 22:00 UTC

Principales Noticias

Ganancias

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1 nov 2024, 21:29 UTC

Principales Noticias

Ganancias

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1 nov 2024, 21:24 UTC

Ganancias

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

Comparación entre iguales

Cambio de precio

Laboratorios Farmaceuticos Rovi SA Esperado

Precio Objetivo

By TipRanks

23.9% repunte

Estimación a 12 meses

Media 99 EUR 23.9%

Máximo 104 EUR

Mínimo 94 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Laboratorios Farmaceuticos Rovi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Laboratorios Farmaceuticos Rovi SA Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

76.2 / 80.2Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

371 / 389 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.